Latus Pharma ApS: Financial statements 2025
CVR: 36974214
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Latus Pharma ApS (CVR 36974214) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK -6,991 and a net result of DKK -6,991 compared with DKK -6,897 the year before. Equity in the 2025 report amounted to DKK 82,569. The solvency ratio was 100%.
- Revenue
- DKK -6,991
- Gross Profit
- DKK -6,991
- Profit/Loss
- DKK -6,991
- Equity
- DKK 82,569
- Total Assets
- DKK 82,569
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | -7 t. | -7 t. | -7 t. | 83 t. | - |
| 2024 | -7 t. | -7 t. | -7 t. | 88 t. | - |
| 2023 | 0 | -11 t. | -11 t. | 94 t. | - |
| 2022 | 0 | -14 t. | -14 t. | 105 t. | - |
| 2021 | 0 | -4 t. | -4 t. | 119 t. | - |
Official annual report
How creditworthy is Latus Pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Latus Pharma ApS has published its annual report for 2024. Revenue came to DKK -6,897, and the net result was DKK -6,897.
About Latus Pharma ApS
Latus Pharma ApS is a Danish company of the type Anpartsselskab based in Køge, founded in 2015. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Jørgen Wittendorff. The company is owned by Jørgen Wittendorff. In 2025, the company reported revenue of DKK -6,991 and a net result of DKK -6,991 compared with DKK -6,897 the year before. Equity in the 2025 report amounted to DKK 82,569.